ArticleScientific reports2025
Sodium new houttuyfonate affects tumor angiogenesis by suppressing FGF1 expression and the p38/MAPK signaling pathway in pancreatic cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pancreatic cancer is one of the deadliest cancers in the world. Phytochemicals are considered as potential anticancer drugs because of their safety and low cost. Sodium new houttuyfonate (SNH) is derived from Houttuynia cordata Thunb. (HCT), which is a famous edible and medicinal plant in China. Although research findings suggest that SNH possesses anticancer properties, its role and mechanisms in pancreatic cancer remain unclear. Using network pharmacology, we identified 49 potential targets of SNH action in pancreatic cancer. In vitro, we confirmed that SNH inhibited the proliferation and invasion, promoted mitochondrial damage and induce apoptosis of PANC-1 cells. In vivo, SNH promoted tumor apoptosis and inhibited pancreatic cancer development in mice. In addition, RNA sequencing demonstrated that SNH exerted anticancer effects by regulating the MAPK (Mitogen-activated protein kinase) signaling pathway and identified FGF1 (Fibroblast growth factor 1) as a key gene in this process. Moreover, FGF1 is also an important gene affecting tumor angiogenesis, which is an important process in tumor development. Therefore, the study demonstrated that SNH inhibited pancreatic cancer progression by down-regulating FGF1 expression and inactivating the p38/MAPK pathway, thereby affecting tumor angiogenesis. Our study provides a potentially effective strategy for the treatment of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.